H.C. Wainwright lowered the firm’s price target on Affimed (AFMD) to $7 from $10 and keeps a Buy rating on the shares. The firm delayed the projected U.S. launch of AFM24 in lung cancer to 2030 from 2028.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AFMD:
- Affimed’s Promising Clinical Update on NSCLC Treatment
- Affimed’s AFM24/atezolizumab combination shows positive results in NSCLC trial
- Affimed price target lowered to $15 from $20 at Wells Fargo
- Affimed reports ‘promising’ Phase 1 efficacy, safety data for AFM28
- Affimed: Acimtamig, AlloNK combination granted RMAT designation by FDA